NexStar Pharm(NXTR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (281)	3/30/1998 2:52:00 PM
From: Steven Yang	Read Replies (1) of 328

To all: I find that NXTR's 10K is available on line. I find, just glancing, that Sumimoto (sp?) is going to pay a milestone payment to NXTR of $3M. I guess that this milestone is the completion of clinical trial. If Am is approved in Japan, it is going to pay NXTR another milestone payment. It will then buy the drug from NXTR at cost, and pay a royalty for Am's sale in Japan. With this extra $3M coming in 98Q1, it seems that NXTR will show a better number for the quarter than expected. Of course, the long term outlook lies in the improved sale of Am in US and in Europe, and the progress on the clinical trial of Mk. MZ: thanks for the info. regarding the market potential of Mk. Bill: When NXTR management says that its competitors are selling their drug below cost, my understanding is that they are selling at a price that they can not recover all the research funding, not that they are selling at a loss on an on-going basis. Steve ps: SEQU has been moving up quite a bit lately. There are some takeover rumors. If it were true, it would be positive for NXTR as well.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next